rnai
rapidli
becom
power
tool
drug
target
discoveri
valid
cell
cultur
larg
displac
effort
antisens
ribozym
consequ
interest
rapidli
grow
extens
applic
vivo
system
anim
diseas
model
human
therapeut
studi
rnai
result
two
basic
method
use
gene
select
inhibit
cytoplasm
deliveri
short
dsrna
oligonucleotid
sirna
mimic
activ
intermedi
endogen
rnai
mechan
nuclear
deliveri
gene
express
cassett
express
short
hairpin
rna
shrna
mimic
micro
interf
rna
mirna
activ
intermedi
differ
endogen
rnai
mechan
nonvir
gene
deliveri
system
divers
collect
technolog
applic
form
rnai
importantli
unlik
antisens
ribozym
system
remark
trait
sirna
lack
depend
chemic
modif
block
enzymat
degrad
although
chemic
protect
method
develop
earlier
system
incorpor
sirna
gener
compat
nonvir
deliveri
system
use
sirna
emerg
rapidli
shrna
part
due
increas
effort
requir
construct
shrna
express
system
select
activ
sequenc
verif
biolog
activ
obtain
contrast
screen
mani
sirna
sequenc
accomplish
rapidli
use
synthet
oligo
surpris
use
sirna
vivo
also
emerg
first
initi
vivo
studi
report
viral
nonvir
deliveri
viral
deliveri
limit
shrna
review
describ
emerg
vivo
applic
nonvir
deliveri
system
rnai
function
genom
provid
foundat
develop
rnai
therapeut
interest
rapid
adapt
ligandtarget
plasmidbas
nanoparticl
rnai
agent
system
grow
capabl
begin
pose
seriou
rival
viral
vector
base
gene
deliveri
activ
sirna
cytoplasm
may
lower
hurdl
therebi
acceler
success
develop
therapeut
base
target
nonvir
deliveri
system
elsevi
inc
rna
interfer
rnai
strong
select
gene
inhibit
rna
interfer
rapidli
displac
antisens
ribozym
prefer
mean
sequencespecif
gene
inhibit
cell
cultur
studi
bantouna
et
al
lu
et
al
mcmanu
sharp
along
rapid
adopt
tool
function
genom
expand
studi
rnai
greatli
enhanc
understand
endogen
gene
inhibit
process
sinc
discoveri
posttranscript
gene
silenc
ptg
plant
also
activ
anim
cell
despit
rapidli
expand
studi
rnai
biolog
still
far
well
understood
major
challeng
grow
appreci
rnai
system
involv
sever
endogen
activ
differ
role
one
earliest
recogn
role
rnai
antivir
respons
trigger
doublestrand
ds
rna
genom
doublestrand
rna
viru
respons
effect
strong
select
gene
inhibit
import
gene
inhibit
function
oper
activ
intermedi
short
fragment
dsrna
genom
call
short
interf
rna
sirna
shown
fig
rnai
antivir
respons
gener
accompani
interferon
event
induc
recognit
dsrna
viral
genom
import
find
introduct
sirna
sequenc
match
endogen
gene
instead
invad
viru
genom
lead
activ
rnai
system
inhibit
endogen
gene
importantli
studi
shown
introduct
artifici
sirna
usual
avoid
interferon
concomit
biolog
respons
mcmanu
sharp
also
rnai
machineri
found
perform
function
cytoplasm
compart
reduc
hurdl
intracellular
sirna
deliveri
compar
gene
therapi
requir
deliveri
nucleu
anoth
major
rnai
role
one
remain
poorli
understood
regul
cellular
activ
modul
endogen
gene
express
function
oper
least
part
activ
intermedi
short
express
rna
imperfect
palindrom
sequenc
call
figur
two
major
pathway
rnai
invok
deliv
synthet
sirna
duplex
cytoplasm
deliv
express
cassett
nucleu
produc
short
hairpin
shrna
export
cytoplasm
either
taken
cytoplasm
risc
machineri
downregul
express
target
gene
vivo
applic
rna
interfer
microinterf
rna
mirna
palindrom
sequenc
form
imperfect
dsrna
segment
loop
singlestrand
ss
rna
one
end
hairpin
type
structur
mimick
express
short
hairpin
rna
shrna
rnai
role
regul
endogen
gene
express
may
help
explain
introduct
sirna
match
endogen
gene
show
strong
select
inhibit
match
endogen
gene
thu
specif
role
rnai
vari
consider
fundament
activ
rnai
block
express
specif
gene
consequ
surpris
differ
rnai
process
similar
mechan
action
share
machineri
share
machineri
may
aid
effort
har
rnai
purpos
allow
greater
util
techniqu
develop
howev
versatil
come
complex
increas
risk
induc
unwant
unexpect
rnai
activ
ultim
though
make
rnai
system
attract
fundament
capabl
achiev
strong
inhibit
specif
gene
strike
select
clearli
essenti
biolog
system
regul
also
goal
target
therapeut
strategi
driven
realiz
success
drug
act
inhibit
specif
target
protein
number
studi
evalu
extent
gene
inhibit
specif
achiev
sirna
case
indic
select
absolut
select
chi
et
al
jackson
et
al
kariko
et
al
semizarov
et
al
sledz
et
al
fact
difficult
distinguish
offtarget
effect
wrong
gene
downstream
biolog
consequ
rnai
silenc
gene
import
aspect
yet
address
rel
select
sirna
versu
gene
sequencebas
method
inhibit
gene
express
ie
antisens
nonetheless
offtarget
effect
observ
common
outcom
find
substanti
sirna
gene
select
thu
use
appropri
control
import
far
common
featur
found
rnai
process
relianc
short
rna
oligonucleotid
whose
sequenc
determin
gene
inhibit
featur
fuel
rapid
adopt
rnai
biolog
research
design
sirna
sequenc
match
gene
interest
sirna
oligonucleotid
origin
identifi
short
dsrna
fragment
gener
rnai
machineri
call
dicer
process
long
dsrna
viral
infect
sirna
fragment
sirna
found
activ
intermedi
use
second
piec
machineri
call
risc
select
mrna
degrad
describ
elsewher
bantouna
et
al
lu
et
al
mcmanu
sharp
mechan
mirna
appear
similar
ident
sirna
one
similar
mirna
also
appear
invok
risc
compon
degrad
homolog
mrna
ribosom
translat
occur
endogen
activ
rnai
regul
endogen
gene
express
clearli
depend
good
specif
strong
inhibit
may
explain
robust
potenc
select
natur
rnai
remain
area
activ
investig
use
short
dsrna
sequenc
prove
extrem
robust
effect
method
inhibit
specif
gene
interest
simpli
depend
larg
identif
uniqu
sequenc
gene
splice
variant
fig
short
period
time
use
sirna
downregul
express
specif
gene
becom
method
choic
cell
cultur
vitro
studi
deliveri
sirna
duplex
specif
target
certain
gene
interest
cell
tissu
typic
perform
sirna
target
individu
gene
multipl
sirna
duplex
inhibit
group
gene
also
possibl
benefici
detriment
effect
sirna
inhibit
specif
gene
induc
phenotyp
chang
cell
analyz
use
variou
mean
includ
biochem
pharmacolog
histolog
assay
current
use
sirna
character
gene
function
particular
explor
potenti
therapeut
drug
target
spread
everi
aspect
biolog
research
fig
phenomenon
result
two
basic
realiti
sirna
prove
potent
robust
easi
use
inhibitor
downregul
individu
gene
power
tool
understand
biolog
function
gene
biochem
pathway
vivo
applic
rna
interfer
develop
control
patholog
latter
led
consider
adopt
sirna
function
genom
look
inhibit
gene
gener
therapeut
benefit
revers
patholog
effect
often
caus
overexpress
gene
howev
approach
clearli
depend
effect
sirna
deliveri
modul
select
express
specif
gene
result
induc
physiolog
pharmacolog
effect
key
requir
identif
effect
site
target
mrna
sequenc
sirna
access
also
applic
effect
transfect
sirna
agent
cytoplasm
compart
critic
bantouna
et
al
mcmanu
sharp
surprisingli
cancer
research
dynam
excit
area
applic
sirna
inhibitor
lu
et
al
howev
research
mani
differ
therapeut
area
invok
applic
sirna
use
research
tool
valid
gene
function
regardless
therapeut
area
success
vitro
transfect
sirna
cell
target
research
led
strong
interest
extend
studi
vivo
system
howev
vivo
deliveri
sirna
specif
tissu
anim
diseas
much
complic
although
increas
number
studi
target
identif
valid
use
sirna
vitro
report
limit
report
vivo
studi
indic
lack
effect
deliveri
method
sirna
agent
key
vivo
applic
deliveri
system
transport
sirna
target
tissu
cell
cytoplasm
shrna
express
cassett
nucleu
much
like
depend
gene
therapi
appropri
deliveri
method
given
extens
effort
nucleic
acid
deliveri
gene
therapi
mani
deliveri
tool
consid
sirna
shrna
deliveri
includ
biologicalbas
vector
synthet
chemicaland
physicalbas
system
consequ
fastgrow
literatur
use
sirna
research
tool
function
genom
emerg
interest
sirna
therapeut
therapeut
applic
even
function
genom
clearli
depend
optim
local
system
deliveri
sirna
vivo
therefor
mean
deliv
sirna
target
tissu
maintain
activ
within
target
cell
target
gene
sequenc
key
aspect
consid
order
fulfil
goal
function
genom
research
therapeut
develop
effect
sirna
vitro
demonstr
inhibit
express
mani
differ
gene
mani
differ
cell
type
virtual
case
result
depend
mean
intracellular
deliveri
although
transfect
sirna
cultur
cell
rel
easi
compar
plasmid
gene
express
system
bantouna
et
al
mcmanu
sharp
wide
varieti
nucleic
acid
deliveri
system
develop
includ
viral
vector
nonvir
approach
achiev
effici
signific
modul
gene
express
mani
type
cell
regardless
whether
system
biolog
shrna
express
vector
davidson
paulson
pardridg
chemic
agent
deliv
synthet
sirna
rnai
tool
use
decreas
gene
express
gene
import
result
phenotyp
chang
extens
vitro
success
vivo
system
emerg
improv
remain
critic
need
applic
sirna
drug
target
research
potenti
clinic
applic
sever
method
develop
util
endogen
rnai
machineri
knock
specif
gene
interest
far
avail
method
reli
introduc
one
mean
anoth
short
doublestrand
rna
oligonucleotid
match
part
gene
interest
origin
method
reli
introduct
cell
synthet
dsrna
oligonucleotid
resembl
natur
sirna
oligonucleotid
artifici
sirna
taken
risc
machineri
use
block
express
endogen
mrna
contain
match
sequenc
approach
remain
promin
method
highthroughput
rnai
research
short
oligonucleotid
synthesi
fast
perform
high
throughput
limit
primarili
cost
synthet
oligonucleotid
need
repeat
chemic
synthesi
grow
effort
develop
around
method
deliv
express
cassett
produc
rnai
intermedi
initi
challeng
approach
difficulti
get
express
two
short
complementari
rna
oligonucleotid
within
cell
result
hybrid
yield
dsrna
oligonucleotid
one
solut
problem
express
singl
rna
palindrom
sequenc
hybrid
form
stemloop
hairpin
structur
much
like
mirna
call
short
hairpin
rna
shrna
theoret
express
cassett
introduc
standard
gene
deliveri
system
includ
viral
nonvir
method
grow
number
effort
report
construct
system
evalu
vivo
applic
davidson
paulson
devro
silver
kobayashi
et
al
pardridg
tiscornia
et
al
xia
et
al
howev
time
effort
need
construct
express
cassett
incorpor
deliveri
system
add
consider
time
cost
set
studi
gene
interest
particularli
true
realiz
sever
sequenc
must
test
find
vivo
applic
rna
interfer
effect
sequenc
unfortun
identif
activ
sequenc
use
synthet
sirna
oligonucleotid
alway
predict
activ
shrna
sequenc
reduc
util
preliminari
sirna
screen
address
problem
effect
express
cassett
identifi
materi
usual
replenish
standard
molecular
biolog
techniqu
wide
rang
nucleic
acid
deliveri
system
devis
without
adapt
viru
thu
fall
broad
categori
call
nonvir
vector
lump
togeth
poorli
defin
class
mani
differ
system
cover
vastli
differ
form
nucleic
acid
likewis
class
cover
wide
varieti
method
formul
deliv
nucleic
acid
enabl
intracellular
deliveri
includ
cation
complex
lipid
polym
plga
microspher
depot
formul
hydrophil
protect
polym
physic
forcebas
deliveri
bombard
nucleic
acidco
gold
particl
electropor
mani
deliveri
method
note
common
featur
convey
nonvir
categori
oper
either
natur
synthet
form
nucleic
acid
eg
plasmid
phosphorothio
antisens
oligonucleotid
addit
success
deliveri
vivo
depend
mani
factor
rout
tissu
uptak
greatest
success
attain
local
deliveri
tissu
eg
plga
microspher
electropor
muscl
deliveri
success
attain
system
deliveri
highpressur
tail
vein
administr
hydrodynam
deliveri
liver
hepatocyt
dotap
lipoplex
lung
tissu
deliveri
method
limit
potenti
applic
human
eg
hydrodynam
deliveri
capabl
enabl
function
genom
research
investig
vivo
criteria
success
differ
lu
et
al
one
import
nonvir
deliveri
method
base
use
cation
transfect
agent
form
complex
oligonucleotid
method
shown
activ
sirna
vivo
commonli
use
transfect
reagent
cation
lipid
produc
lipoplex
complex
spagnou
et
al
sorensen
et
al
examin
deliveri
cation
liposomebas
administr
mice
sirna
combin
match
plasmid
encod
green
fluoresc
protein
gfp
found
inhibit
vivo
gfp
plasmid
gene
express
furthermor
studi
evalu
intraperiton
inject
antitnfsirna
inhibit
lipopolysaccharideinduc
tumor
necrosi
factor
tnf
gene
express
wherea
secret
interleukin
il
inhibit
found
gene
therapi
effort
develop
nonvir
deliveri
method
achiev
tumortarget
sirna
deliveri
activ
intraven
administr
proven
difficult
one
studi
report
use
cation
chemic
deriv
cardiolipin
form
lipoplex
sirna
target
craf
also
known
oncogen
inhibit
tumor
growth
sequencespecif
manner
studi
neglect
evalu
whether
target
gene
specif
inhibit
chien
et
al
confirm
target
inhibit
help
reveal
effect
attribut
rnai
mechan
found
earlier
studi
use
aqueou
administr
sirna
filleur
et
al
cation
lipoplex
polyplex
system
form
foundat
numer
effort
develop
ligandtarget
gene
deliveri
system
studi
begun
emerg
adapt
system
sirna
kakizawa
et
al
khan
et
al
shiffeler
et
al
result
obtain
use
ligand
target
plasmid
tumor
neovasculatur
suggest
system
tumor
therapeut
use
gene
deliveri
possibl
hood
et
al
ogri
et
al
walker
woodl
et
al
approach
focus
deliveri
endotheli
cell
tumor
blood
vessel
effici
plasmid
express
also
limit
traffick
nucleu
thought
inadequ
sirna
activ
cytoplasm
reduc
challeng
result
publish
use
system
administr
target
nanoplex
use
argglyasp
rgd
motif
peptid
ligand
combin
select
local
neovasculatur
deliveri
sirna
inhibit
vascular
endotheli
growth
factor
vegf
pathway
gene
express
drive
angiogenesi
whether
tumor
eye
diseas
kim
et
al
schiffel
et
al
importantli
studi
result
show
sirna
sequencespecif
target
gene
inhibit
patholog
tissu
system
introduc
dual
target
offer
promis
increas
select
target
therapeut
develop
advanc
cation
complex
form
layer
nanoparticl
appear
promis
therapeut
applic
sirna
metastat
cancer
mani
angiogenesisrel
diseas
nonvir
vector
mani
advantag
especi
therapeut
viral
vector
exampl
immunogen
viral
vector
preclud
multipl
administr
result
sever
toxic
limit
chromosom
integr
result
safeti
concern
also
avoid
nonvir
vector
potenti
safeti
issu
limit
function
genom
immunogen
side
effect
obscur
result
need
avoid
clearli
effect
sirna
deliveri
crucial
vivo
function
genom
ie
inhibit
gene
express
signific
number
cell
mean
emul
biolog
effect
drug
target
protein
emul
mean
sirna
need
deliv
approxim
percentag
cell
cell
tissu
affect
candid
drug
mention
viral
vector
equal
import
requir
nonvir
vector
deliveri
without
signific
vivo
applic
rna
interfer
background
activ
deliveri
method
nonvir
deliveri
method
tend
much
lower
level
biolog
effect
gene
rel
viral
vector
mani
protein
compon
deliv
rnai
agent
vivo
basic
fall
two
approach
local
system
administr
approach
uniqu
suitabl
particular
tissu
type
biolog
studi
system
use
independ
reach
target
organ
mean
verifi
observ
gene
inhibit
outcom
due
deliveri
method
exampl
skin
muscl
better
access
use
local
deliveri
wherea
lung
tumor
reach
effici
local
system
deliveri
choic
local
system
deliveri
larg
depend
tissu
cell
type
target
expect
outcom
sirnamedi
gene
knockdown
term
biolog
readout
addit
choic
usual
part
entir
consider
studi
design
involv
vector
carrier
administr
rout
approach
sirna
deliveri
vivo
increas
data
show
sirna
potent
sequencespecif
inhibitor
mani
tissu
type
increas
number
clinic
protocol
appear
treat
eye
diseas
nucleic
acid
drug
antisens
rna
aptam
clinic
deliveri
approach
appear
suitabl
sirna
administr
depend
local
administr
use
model
retin
neovascular
induc
laser
damag
reich
colleagu
deliv
nonformul
sirna
specif
murin
vegf
subretin
space
observ
signific
reduct
eye
angiogenesi
importantli
unlik
antisens
rna
aptam
work
indic
chemic
protect
sirna
essenti
least
intravitr
compart
eye
use
differ
murin
model
one
herpet
stromal
ketat
develop
herp
simplex
viru
infect
laboratori
barri
rous
also
report
use
polyplex
local
administr
sirna
inhibit
vegf
pathway
kim
et
al
work
compar
local
system
target
deliveri
discuss
later
seem
clear
local
ocular
deliveri
sirna
differ
rout
differ
formul
use
inhibit
gene
suffici
gene
function
studi
work
also
provid
strong
support
therapeut
applic
sirna
ocular
diseas
especi
ocular
neovascular
brain
tissu
foundat
central
nervou
system
cn
obvious
import
biolog
system
one
repres
consider
interest
function
genom
therapeut
tissu
one
capabl
inhibit
gene
select
vivo
either
applic
especi
critic
nerv
function
depend
actual
nerv
network
within
brain
buckingham
et
al
initi
effort
brain
deliveri
focus
express
rnai
construct
davidson
paulson
dorn
et
al
evalu
infus
aqueou
solut
chemic
protect
sirna
oligonucleotid
directli
brain
found
select
gene
inhibit
could
obtain
howev
special
natur
latter
method
includ
special
chemic
modif
sirna
surgic
implant
infus
pump
deliv
high
dose
limit
use
mani
laboratori
interest
area
studi
use
cation
formul
deliveri
sirna
brain
found
deliveri
effect
test
lipoplex
test
polyplex
hassani
et
al
success
observ
divers
studi
show
promis
sirna
deliveri
brain
tissu
function
genom
long
term
good
potenti
therapeut
applic
function
valid
tumorigen
gene
intratumor
deliveri
sirna
attract
approach
rapid
extens
sirna
function
genom
studi
vitro
well
accept
studi
preclin
human
xenograft
tumor
model
ding
et
al
also
well
accept
key
step
stone
clinic
investig
limit
lack
good
local
tumor
deliveri
unfortun
like
earlier
gene
therapi
studi
local
deliveri
sirna
tumor
effici
either
aqueou
solut
socal
nake
nucleic
acid
standard
transfect
reagent
includ
best
cation
lipid
polym
fact
local
administr
aqueou
sirna
tumor
found
less
effect
distal
system
administr
endogen
report
gene
filleur
et
al
studi
effect
observ
distal
administr
attribut
rnai
activ
author
conclud
tumor
deliveri
inadequ
work
begun
emerg
local
tumor
deliveri
sirna
show
suffici
gene
inhibit
target
valid
lu
et
al
minakuchi
et
al
nonvir
deliveri
nucleic
acid
airway
activ
area
part
due
intens
effort
develop
therapi
treat
cystic
fibrosi
patient
overwhelm
immun
respons
adenovir
vector
vivo
applic
rna
interfer
effort
pulmonari
nucleic
acid
deliveri
turn
nonvir
carrier
draw
upon
gener
reduc
toxic
immun
respons
unfortun
nonvir
method
yield
posit
result
clinic
investig
may
effect
sirna
given
lack
depend
nuclear
deliveri
evid
appear
sirna
effect
knockdown
endogen
gene
zhang
et
al
viral
protein
group
rna
virus
eg
influenza
ge
et
al
tompkin
et
al
sar
coronaviru
li
et
al
result
signific
effect
antivir
infect
variou
mammalian
cell
system
vitro
proven
sirna
influenza
evalu
vivo
pulmonari
deliveri
use
standard
nonvir
vector
found
inhibit
influenza
viru
pulmonari
infect
ge
et
al
tompkin
et
al
howev
deliveri
method
strong
candid
clinic
applic
better
method
need
separ
studi
clinic
feasibl
intranas
deliveri
system
use
sar
viru
sirna
result
use
primat
diseas
model
found
good
evid
safeti
efficaci
li
et
al
thu
appear
mani
nonvir
gene
deliveri
system
applic
pulmonari
deliveri
sirna
tissu
skeletalmuscl
system
joint
skelet
muscl
rel
access
local
administr
method
thu
key
use
sirna
sequenc
direct
gene
target
implic
rheumat
musculoskelet
diseas
effect
local
deliveri
enabl
intracellular
deliveri
sirna
agent
diseas
site
specif
specif
cellular
compon
diseas
patholog
rutz
scheffold
direct
inject
sirna
molecul
report
hydrodynam
pressur
isol
limb
hagstrom
et
al
formul
cation
lipid
polym
consid
local
deliveri
tend
induc
inflamm
contraind
arthrit
diseas
studi
also
plasmid
deliveri
skelet
muscl
eletropor
proven
robust
method
recent
appli
sirna
deliveri
golzio
et
al
extens
method
inflam
joint
arthriti
model
shown
promis
method
function
genom
studi
schiffel
et
al
clinic
applic
approach
yet
describ
ultim
biolog
inflamm
immun
respons
central
rheumat
arthrit
diseas
may
benefit
cell
target
end
use
ligandtarget
nanoparticl
even
local
intraarticular
inject
attract
potenti
mean
achiev
gene
inhibit
without
exacerb
patholog
phenotyp
deliveri
system
first
publish
result
show
activ
sirna
mammal
accomplish
feat
deliveri
mous
liver
achiev
use
hydrodynam
deliveri
rapid
inject
larg
volum
aqueou
solut
mous
tail
vein
creat
high
pressur
vascular
circul
lead
extens
deliveri
hepatocyt
lewi
et
al
mccaffrey
et
al
song
et
al
zender
et
al
studi
use
hydrodynam
administr
also
found
poor
activ
aqueou
sirna
given
tradit
intraven
administr
even
chemic
stabil
sirna
use
layzer
et
al
unlik
earlier
find
antisens
oligonucleotid
studi
show
sirna
inhibit
exogen
plasmid
express
also
endogen
hepatocyt
gene
express
success
impli
deliveri
sirna
liver
result
uptak
major
hepatocyt
found
plasmid
deliveri
interestingli
recent
studi
found
aqueou
administr
sirna
nt
induc
nonspecif
interferon
respons
heidel
et
al
hydrodynam
administr
procedur
allow
use
sirna
mice
gene
function
drug
target
valid
studi
sen
et
al
zender
et
al
limit
larg
research
liver
function
metabol
liver
infecti
diseas
hepat
although
particular
method
clinic
feasibl
human
patient
effect
approach
gene
function
valid
song
et
al
inject
fa
sirna
achiev
downregul
fa
mrna
fa
protein
mous
hepatocyt
effect
persist
without
diminut
day
zender
colleagu
deliv
nucleotid
sirna
caspas
result
inhibit
caspas
gene
express
liver
therebi
prevent
fa
mediat
apoptosi
giladi
colleagu
use
hydrodynam
deliveri
sirna
inhibit
level
hepat
b
viral
transcript
viral
antigen
viral
dna
liver
sera
adenoviru
also
appli
liver
deliveri
express
rnai
method
mainli
offer
orthogon
deliveri
approach
confirm
find
due
gene
inhibit
specif
deliveri
method
although
hydrodynam
deliveri
adenovir
vector
clinic
accept
method
two
system
rel
high
hepatocyt
effici
power
tool
hepatocyt
function
genom
studi
target
system
sirna
deliveri
liver
also
attract
approach
develop
ren
et
al
clearli
livertarget
deliveri
system
clinic
feasibl
develop
sirnabas
therapeut
treatment
variou
liverrel
metabol
vivo
applic
rna
interfer
hepat
viral
diseas
one
altern
method
livertarget
deliveri
sirna
use
chemic
modif
oligonucleotid
suggest
work
cholesterol
conjug
soutschek
et
al
howev
work
show
least
three
challeng
must
address
adequ
protect
sirna
oligonucleotid
biolog
degrad
en
rout
liver
protect
sirna
oligonucleotid
rapid
glomerfiltr
kidney
urin
actual
import
stabil
select
uptak
target
hepatocyt
use
cholesterol
conjug
found
requir
high
dose
suggest
distribut
widespread
rather
liver
target
effort
attain
liver
target
sirna
warrant
although
primari
tumor
often
reach
local
administr
malign
tumor
grow
fast
spread
throughout
bodi
via
blood
lymphat
system
unpredict
uncontrol
growth
make
malign
cancer
danger
fatal
form
cancer
metastat
tumor
establish
distant
locat
usual
encapsul
thu
amen
system
deliveri
therefor
local
deliveri
sirna
therapeut
agent
limit
tumor
type
headandneck
cancer
melanoma
function
genom
local
administr
method
discuss
earlier
meet
requir
studi
act
primari
tumor
even
xenograft
model
form
basi
cancer
biolog
research
howev
therapeut
system
deliveri
sirna
need
system
deliveri
impos
sever
requir
greater
hurdl
local
deliveri
sirna
must
provid
increas
oligonucleotid
stabil
blood
local
environ
enter
target
cell
addit
often
requir
sirna
pass
multipl
tissu
barrier
reach
target
cell
may
benefit
protect
loss
activ
within
target
cell
sorenson
et
al
describ
use
lipoplex
gene
deliveri
system
system
deliveri
sirna
attain
strong
lung
deliveri
found
plasmid
dna
use
work
sirna
lipoplex
form
cardiolipid
analogu
show
phenotyp
effect
tumor
growth
lack
confirm
rnai
activ
tumor
suggest
much
distribut
lung
expect
lipoplex
emerg
target
nanoparticl
system
initi
plasmid
dna
oligonucleotid
cancer
much
promis
hood
et
al
pun
et
al
woodl
et
al
natur
system
protect
deliv
isol
dna
suggest
adapt
sirna
oligonucleotid
result
support
conclus
use
rgd
peptid
liganddirect
nanoparticl
antiangiogen
treatment
cancer
dubey
et
al
system
sirna
deliveri
schiffel
et
al
result
provid
grow
support
develop
system
sirna
treatment
cancer
grow
proof
concept
antiangiogen
modal
review
elsewher
lu
et
al
rgd
ligandtarget
nanoparticl
target
neovasculatur
also
studi
ocular
neovascular
model
kim
et
al
result
strengthen
support
approach
clinic
feasibl
method
sirna
therapeut
also
provid
demonstr
sirna
sever
gene
combin
nanoparticl
give
better
inhibit
diseas
patholog
cours
direct
mean
translat
system
gene
therapi
deliveri
method
rnai
use
shrna
express
method
time
though
advantag
disadvantag
system
tumor
deliveri
expressionbas
rnai
versu
sirna
oligonucleotidebas
rnai
yet
fulli
elucid
one
clear
advantag
sirna
howev
rapid
differ
sirna
sequenc
match
gene
studi
importantli
sirna
facilit
rapid
studi
interact
gene
combin
sirna
oligonucleotid
easi
effect
kim
et
al
tradit
approach
identifi
gene
involv
specif
biolog
process
begin
determin
gene
correl
occurr
process
ie
gene
upor
downregul
cell
tissu
biolog
system
interest
appli
patholog
process
approach
gener
larg
pool
upregul
gene
candid
drug
target
howev
success
approach
limit
correl
insuffici
causat
efficaci
consequ
tool
select
downregul
individu
gene
within
cell
tissu
patholog
process
wide
recogn
valuabl
mean
understand
gene
function
especi
facilit
discoveri
protein
target
drug
intervent
sirna
prove
potent
robust
mean
import
object
rapidli
adopt
prefer
function
genom
tool
least
cell
cultur
buckingham
et
al
one
key
hurdl
drug
target
discoveri
valid
directli
anim
diseas
model
lack
effect
vivo
nucleic
acid
deliveri
method
antisens
activ
anim
limit
gener
intraven
administr
aqueou
formul
use
inhibit
liver
gene
function
use
hydrodynam
deliveri
sirna
layzer
et
al
lewi
et
al
mccaffrey
et
al
sen
et
al
one
way
use
vivo
applic
rna
interfer
sirna
gene
inhibit
liver
gene
function
key
element
challeng
often
larg
amplitud
inhibit
overexpress
gene
signific
effect
phenotyp
observ
requir
larg
phenotyp
effect
appear
bigger
challeng
therapeut
gene
function
studi
particularli
sever
class
gene
protein
cancer
tumorigenesi
process
thought
result
abnorm
overexpress
oncogen
growth
factor
mutant
tumor
suppressor
even
though
underexpress
protein
also
play
critic
role
effort
identifi
valid
tumorigen
target
focus
mainli
target
overexpress
tumor
tissu
promot
tumorigenesi
mean
enabl
develop
small
molecul
antibodi
anticanc
drug
act
inhibitor
mechan
rapidli
increas
number
report
demonstr
sirna
shrna
abl
knockdown
tumorigen
gene
vitro
emerg
report
vivo
lu
et
al
xie
et
al
studi
design
reveal
whether
gene
target
play
tumorigen
role
use
sirna
duplex
specif
target
mrna
sequenc
knock
express
observ
whether
effect
patholog
direct
specif
effect
one
method
describ
uniqu
target
identif
approach
lu
et
al
name
efficacyfirst
discoveri
method
util
effici
nucleic
acid
deliveri
xenograft
tumor
induc
phenotyp
effect
tumor
growth
rate
method
verifi
valid
candid
gene
control
role
tumor
growth
behavior
use
method
pool
gene
target
identifi
chang
express
correl
chang
tumor
growth
rate
ie
express
correl
efficaci
among
wellknown
cancer
cell
growth
factor
vegf
vegf
repres
two
wide
recogn
highli
valid
target
studi
sirnamedi
downregul
endogen
gene
clinic
relev
anim
model
use
part
function
genom
studi
cancer
lu
et
al
mark
tumor
growth
inhibit
observ
follow
repeat
deliveri
sirna
specif
hvegf
accompani
knockdown
growth
factor
mrna
protein
level
result
illustr
feasibl
use
sirna
deliveri
anim
tumor
model
drug
target
valid
accord
abil
achiev
efficaci
lu
et
al
vivo
deliveri
sirna
enabl
differenti
gene
find
play
diseasecontrol
role
tumor
growth
valid
process
call
diseasecontrol
valid
base
tumor
efficaci
sirna
vivo
clinic
relev
xenograft
tumor
model
give
clear
indic
import
specif
protein
drug
target
lu
et
al
sirna
studi
cell
cultur
provid
better
understand
mechan
action
candid
gene
target
lay
foundat
use
sirna
diseas
model
effect
vivo
function
genom
requir
lu
et
al
hi
gh
ef
ficienc
vivo
deliveri
good
activ
clinic
relev
diseas
mo
de
l
f
r
th
e
c
lin
ca
l
nd
ic
io
n
f
nt
er
es
r
e
su
lt
bt
e
e
nd
ic
e
ha
gene
inhibit
sirna
sequencespecif
effect
also
sustain
obtain
rel
side
effect
low
nois
level
importantli
approach
offer
abil
gain
insight
gene
protein
associ
later
stage
patholog
appli
establish
diseas
tissu
capabl
move
rapidli
cell
cultur
clinic
relev
diseas
model
promis
revolution
speed
drug
target
identifi
valid
drug
discoveri
equal
import
use
sirna
vivo
offer
prospect
rapidli
obtain
better
understand
particular
target
use
achiev
clinic
meaning
therapeut
intervent
diseas
capabl
also
import
basic
research
diseas
biolog
sinc
select
gene
inhibit
tool
one
construct
quickli
oper
anim
model
facilit
rapid
expans
knowledg
thu
emerg
capabl
vivo
deliveri
sirna
greatli
expand
power
tool
function
genom
specif
potenc
sirna
cell
cultur
anim
studi
suggest
may
use
therapeut
agent
schiffel
et
al
howev
develop
sirna
therapeut
agent
face
number
challeng
especi
system
rout
administr
critic
hurdl
vivo
deliveri
attain
adequ
deliveri
diseas
tissu
cell
grow
number
studi
report
evalu
prospect
sirna
therapeut
summar
tabl
surprisingli
vivo
stabil
proven
major
ratelimit
barrier
even
intraven
administr
fact
rapid
excret
sirna
blood
urin
occur
degrad
nonetheless
effort
underway
increas
biolog
stabil
primarili
via
medicin
chemistri
origin
develop
oligonucleotid
howev
chemic
stabil
address
key
requir
better
pharmacokinet
tissu
distribut
conjug
lipophil
residu
increas
serum
protein
bind
improv
pharmacokinet
oligonucleotid
alter
biodistribut
reduc
urinari
excret
observ
soutschek
et
al
ultim
chemic
modif
must
also
address
requir
enter
target
cell
overcom
endosom
intracellular
barrier
retain
activ
cellular
rnai
machineri
differ
approach
solv
problem
use
ligandtarget
nanoparticl
kim
et
al
pardridg
schiffel
et
al
show
good
activ
even
without
chemic
stabil
fundament
think
behind
approach
rna
interfer
natur
process
involv
complic
vivo
applic
rna
interfer
cellular
mechan
sirna
predomin
intermedi
play
sequencespecif
silenc
function
therefor
preserv
biochem
authent
sirna
improv
vivo
deliveri
effici
nanoparticl
formul
best
chanc
success
therapeut
applic
importantli
best
chanc
reduc
unwant
side
effect
although
local
topic
deliveri
sirna
may
fit
well
certain
diseas
applic
system
deliveri
sirna
much
broader
therapeut
applic
ideal
system
sirna
system
deliveri
nanoparticl
liganddirect
tissu
local
fig
threestag
system
abl
first
protect
sirna
duplex
excret
degrad
bodi
fluid
blood
time
avoid
aggreg
nonspecif
bind
nanoparticl
system
also
target
capabl
reach
diseas
tissu
specif
particl
bind
enter
target
cell
sirna
content
releas
action
sirna
specif
inhibit
express
diseasecaus
gene
protein
clinic
benefit
achiev
describ
earlier
layer
nanoplex
system
describ
combin
neovasculaturetarget
figur
dualtarget
antiangiogenesi
sirna
system
deliv
use
liganddirect
nanoparticl
vivo
applic
rna
interfer
nanoparticl
give
cytoplasm
deliveri
highli
potent
sirna
activ
cytoplasm
nanoparticl
system
appear
promis
therapeut
applic
sirna
metastat
cancer
mani
angiogenesi
relat
diseas
modular
design
nanoparticl
permit
incorpor
ligand
applic
sirna
deliveri
diseas
use
rnai
therapi
attract
directli
silenc
pathogen
gene
diseasecaus
mutant
gene
diseas
mechan
becom
increasingli
clear
applic
develop
silenc
newli
identifi
gene
involv
known
pathogen
pathway
exampl
obviou
sirna
target
treatment
alzheim
diseas
ad
site
appcleav
enzym
bace
requir
product
peptid
present
elev
level
cortex
peopl
ad
one
greatest
prospect
therapeut
abil
develop
therapeut
agent
control
multipl
target
one
aspect
sirna
offer
consider
promis
rel
current
set
target
therapeut
antibodi
consider
evid
show
mani
type
human
diseas
result
overexpress
multipl
diseasecaus
gene
thu
potent
specif
properti
sirna
control
sole
chang
sequenc
suggest
combin
easili
manag
kim
et
al
show
facil
sirna
provid
combin
therapeut
sirna
oligo
cocktail
target
multipl
gene
patholog
achiev
much
better
therapeut
efficaci
approach
base
two
import
fact
although
inhibitori
sirna
duplex
sequenc
specif
use
ident
chemistri
dsrna
oligonucleotid
howev
mani
human
diseas
result
overexpress
multipl
endogen
exogen
diseasecaus
gene
use
sirna
oligo
cocktail
target
multipl
diseasecaus
gene
repres
advantag
therapeut
approach
synergist
effect
nevertheless
even
singl
agent
sirna
tremend
therapeut
potenti
realiz
clinic
feasibl
deliveri
develop
